Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Dermatologic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 119Carcinoma, Hepatocellular 69Ovarian Neoplasms 62Neoplasms 36Carcinoma, Non-Small-Cell Lung 34Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 22Colonic Neoplasms 21Breast Neoplasms 19Neoplasm Metastasis 18Endometrial Neoplasms 18Stomach Neoplasms 15Uterine Cervical Neoplasms 14Rectal Neoplasms 14Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Gastrointestinal Neoplasms 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Bevacizumab × 1 year × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡